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Objectives. We investigated whether endogenous pulmonary big
endothelin has arrhythmogenic properties under normal condi-
tions and in heritable hyperlipidemia.
Background. Endothelin (ET), one of the most potent vasocon-
strictors, is known to induce ventricular arrhythmias. It is un-
clear, however, whether its precursor, big endothelin, released
from the lung, contributes to arrhythmogenesis.
Methods. In a lung-heart model in which a Langendorff heart is
serially perfused with the effluent from the isolated lung of the
same animal, we evaluated arrhythmias in control and in Wa-
tanabe heritable hyperlipidemic (WHHL) rabbits.
Results. In both controls (n 5 12) and WHHL (n 5 8), serial
perfusion evoked a decrease in coronary flow (controls, 211 6 3%;
WHHL, 225 6 6%) and a fourfold increase of ventricular
extrasystoles (VES) (controls, 40.7 6 8; WHHL, 40.2 6 5
VES/40 min, p < 0.05). However, WHHL developed more and
longer nonsustained ventricular tachycardias (VT) compared with
controls (incidence, 1.38 6 1.1 vs. 0.33 6 0.5 VT/40 min, p < 0.05;
length, 14.36 6 3.1 vs. 7.25 6 1.5 beats/VT, p < 0.05). Arrhythmias
were not ischemia-induced because corresponding mechanical
flow reduction had no arrhythmogenic effect (n 5 6 in controls
and WHHL). Although vasoconstriction disappeared entirely,
arrhythmias were only partly suppressed by ETA antagonists
(BQ-123, 2 mmol/liter; A-127722, 20 mmol/liter). The ET-
converting enzyme inhibitor phosphoramidon (50 mmol/liter)
completely suppressed arrhythmias and vasoconstriction. The
ETB antagonists (IRL-1038, 4 mmol/liter; IRL-1025, 5 mmol/liter)
had no effect (n 5 6).
Conclusions. Endogenous pulmonary big ET produces arrhyth-
mogenic effects that are aggravated in heritable hyperlipidemia.
These effects, requiring coronary conversion of big ET into ET, are
partly ETA-mediated and ETB-independent.
(J Am Coll Cardiol 1998;32:1773–8)
©1998 by the American College of Cardiology
Endothelin (ET), one of the most potent vasoconstricting
and cardiotonic peptides (1), has attracted clinical interest
owing to the fact that elevated plasma concentrations have
been found in many pathophysiological situations, such as
congestive heart failure (2,3) and pulmonary hypertension
(4). Elevations in ET and its precursor, big endothelin, have
also been described in acute myocardial infarction (5). The
potential relevance of this finding has been examined in
several animal models. These studies have demonstrated
that exogenous ET causes coronary vasoconstriction and, at
higher doses, ventricular arrhythmias, including ventricular
fibrillation (6). These arrhythmogenic properties have been
attributed to myocardial ischemia following intense ET-
mediated coronary vasoconstriction. However, recent elec-
trophysiological experiments conducted on cardiac tissues
suggest that ET may also possess direct arrhythmogenic
properties (7,8). Despite the demonstrated arrhythmogenic
effects of the mature peptide, little is known about how its
precursor, big ET, contributes to these properties.
By means of a new lung-heart model, we have recently
shown (9) that a basal luminal pulmonary release of big ET
occurs in isolated perfused rabbit lungs, unaccompanied by
relevant amounts of the mature peptide, ET. Pulmonary big
ET, locally converted into ET during coronary passage, causes
an ETA receptor-mediated decrease in coronary flow by 11%
in controls. Among Watanabe heritable hyperlipidemic
(WHHL) rabbits, in contrast, we determined that an identical
release of pulmonary big ET caused a significantly stronger
decrease in coronary flow by 25% of baseline levels.
In this study we investigated whether this endogenous
pulmonary big ET has arrhythmogenic properties, and, if so,
whether these effects are enhanced in heritable hyperlipid-
emia.
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Methods
Preparation. Male New Zealand White (NZW) rabbits
and male WHHL rabbits (14 weeks old, Charles River),
weighing 2.0 to 2.3 kg, were used for these experiments, which
were performed in accordance with protocols approved by the
institutional Animal Care and Use Committee. The study
conforms to the guidelines of the American Heart Association
on Research Animal Use adopted on November 11, 1984.
Watanabe rabbits are frequently used as an atherosclerosis
model: owing to a heritable low density lipoprotein receptor
defect, these animals develop hyperlipidemia from birth on
(10), with the ensuing atherosclerotic process closely resem-
bling that observed in familial hypercholesterolemia in humans
(11).
For excision of heart and lung from the same animal, the
rabbits were anesthetized with thiopental sodium (intraperito-
neally 40 to 80 mg/kg body weight [BW]) after anticoagulation
with heparin (1500 U/kg BW). Hearts and lungs were removed
for isolated extracorporeal perfusion as previously described
(9).
A tracheotomy permitted ventilation with a Siemens Servo
910 respirator (Siemens-Elema) at 50 breaths/min, with a tidal
volume of 10 to 12 ml/kg BW, and 1 mm Hg positive
end-expiratory pressure. The inspired gas mixture consisted of
95% O2 and 5% CO2.
A median sternotomy was performed, and cannulas were
placed into the pulmonary artery and the aorta. The heart was
rapidly and carefully excised and perfused retrogradely
through the aorta (Langendorff technique) with modified
Krebs-Henseleit buffer (37.5°C). The pH was adjusted to 7.35
to 7.40, and the buffer oxygenated with a mixture of 95% and
5% CO2. Left and right ventricular pressures (LVP, RVP)
were measured by means of a polyethylene catheter with a
small latex balloon at its top. This device was inserted into the
ventricular cavity and filled with saline solution until end-
diastolic LVP and RVP stabilized between 1 to 3 mm Hg (0.13
to 0.40 kPa). Coronary flow rates were determined by an
ultrasonic flowprobe (Transonic Systems). We accepted only
those hearts that achieved a contractile performance of more
than 70 mm Hg (9.46 kPa) LVPmax, more than 1000 mm Hg/s
(135.35 kPa/s) rate of pressure development dp/dtmax and
more than 1000 mm Hg/s (135.35 kPa/s) rate of pressure
decline, dp/dtmin. These criteria correspond to the 10% per-
centiles obtained by analyzing data from preceding experi-
ments.
Meanwhile, the pulmonary vasculature was flushed in a
nonrecirculatory mode with Krebs-Henseleit buffer (same
composition, pH 5 7.35 to 7.40) to remove residual blood
elements. Lungs were suspended in a temperature-equilibrated
humidified chamber (37.5°C) from a force transducer that mon-
itored changes in lung weight. Pulmonary flow was gradually
increased to 100 ml/min of nonrecirculatory perfusion. Only those
lungs were selected for the present study that showed a constant
pulmonary arterial pressure (6 to 10 mm Hg [0.81 to 1.35 kPa],
zero-referenced at hilus), constant peak inflation pressures of 7 to
10 mm Hg [0.95 to 1.35 kPa], no weight gain (,0.5 g/h), and no
signs of hemorrhage, edema or atelectasis.
Lung-heart model. The apparatus used in our investigation
was manufactured by Hugo Sachs Electronics. Modification of
the device allows rapid switching from separate to serial organ
perfusion. Once switching has taken place, the amount of lung
effluent that equals coronary flow is rapidly conveyed (2 s) to
the heart apparatus. There it is oxygenated prior to becoming
perfused, at constant pressure, through the coronary vessels.
Experimental Protocol
Serial perfusion. Hearts and lungs were permitted to sta-
bilize over 40 min, during which time both endothelium-
dependent and -independent relaxation of the coronary arter-
ies were assessed with the use of acetylcholine (2 mmol/liter),
substance P (200 pmol/liter), sodium nitroprusside (4 mmol/
liter) and nitroglycerin (4 mmol/liter). The lungs were rinsed
and controlled for pressure and weight constancy. Following
this initial period of separate organ perfusion, the systems were
switched to serial perfusion for an additional 40 min. To
determine ET and big ET, samples of pulmonary and coronary
effluent were taken simultaneously at the end of separate
perfusion and at 50, 500 and 1500 s during serial perfusion. We
have recently reported this subset of results (9).
For all groups, registration of epicardial electrocardiogram
(ECG) took place throughout the control and the serial
periods, by using two stainless steel electrodes attached di-
rectly to the right atrium and the base of the left ventricle. The
signal was digitalized and sampled with a rate of 500 Hz.
Arrhythmias were classified according to the following
characteristics: Isolated ventricular extrasystoles (VES) were
defined as discrete and identifiable premature QRS complexes,
preceded by a shortened beat-to-beat interval. Ventricular
tachycardia was defined as a run of four or more consecutive
morphologically similar ventricular complexes. Ventricular fi-
brillation was defined as a signal for which individual QRS
deflections could not be distinguished from one another (im-
plying morphological instability) and for which the rate could
no longer be measured (12). Both the incidence and the types
of arrhythmias were determined and reported for the entire
interval of 40 min.
Mechanical flow reduction. Six isolated hearts of both
NZW and WHHL rabbits underwent mechanical flow reduc-
tion (i.e., volume-controlled perfusion) to determine whether
it was possible to attribute arrhythmogenic events to alter-
Abbreviations and Acronyms
ECE 5 endothelin-converting enzyme
ET 5 endothelin
NZW 5 New Zealand White rabbits
VES 5 ventricular extrasystole
VT 5 ventricular tachycardia
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ations in coronary flow. Mechanical flow reduction mimicked
the average coronary flow response during serial perfusion.
Administration of exogenous big ET and ET. In an attempt
to reproduce the results obtained in the serial perfusion
experiments, and to compare them with the effects of exoge-
nous vasoconstrictors, isolated hearts of both NZW (n 5 6)
and Watanabe rabbits (n 5 6) received a 40-min coronary
infusion of human ET-1 (5 pmol/liter) or human big ET-1 (5
pmol/liter).
Pharmacological interventions. The following reagents
were applied prior to switching from separate to serial perfu-
sion, with application of each reagent to different subgroups
(n 5 4) of both the control and the WHHL rabbits: DesArg9-
[Leu]8-bradykinin (5 mmol/liter), a bradykinin-1 receptor an-
tagonist (13); Hoe-140 (1 mmol/liter), a bradykinin-2 receptor
antagonist (13) and captopril (5 mmol/liter), an angiotensin-
converting enzyme inhibitor (14). Infusion took place into
coronary circulation. Meclofenamic acid (10 mmol/liter), a
cyclooxygenase inhibitor (15), was applied into pulmonary
artery.
Furthermore, we tested the following substances for their
capability of influencing the effects observed during serial
perfusion (n 5 6 per subgroup): the nonselective endothelin
antagonist PD-145065 (10 mmol/liter) (16), two different ETA
receptor antagonists, BQ-123 (2 mmol/liter) (17) and A-127722
(20 mmol/liter) (18), the ETB antagonists IRL-1038 (4 mmol/
liter) (19) and IRL-1025 (5 mmol/liter) (19), as well as the ECE
(endothelin-converting enzyme) inhibitor phosphoramidon (50
mmol/liter) (20).
Reagents. The following were purchased from Sigma
Chemical: acetylcholine, nitroglycerin, substance P (Arg-Pro-
Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2), sodium nitro-
pruss ide, meclofenamic acid (2-[(2 ,6-dichloro-3-
methylphenyl)-amino]benzoic acid), captopril ([2S]-1-[3-
mercapto-2-methyl-propionyl]-L-proline), desArg9-[Leu8]-
bradykinin, BQ-123 (cyclo[D-Asp-Pro-D-Val-Leu-D-Trp]),
human ET-1, human big ET-1 and phosphoramidon (N-(a-
rhamnopyranosyloxyhydroxyphosphinyl)-Leu-Trp sodium
salt). Parke Davis and Abbott generously provided PD-145065
(Ac-(D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-
yl))Gly-L-Leu-L-Asp-L-Ile-L-Trp disodium salt, lot B) and
A-127722 ([2R,3R,4S]-2-(4-methoxyphenyl)-4-(1,3-
benzodioxol-5-yl)-1-[ [ N , N -dibutyl-amino)-carboxyl]-
methyl]pyrrolidine-3-carboxylic acid), respectively. Both
IRL-1038 ([Cys11-Cys15]-endothelin-1(11-21)) and IRL-1025
([Cys11-Leu15-endothelin-1(11-21)) were gifts from Ciba
International Research Laboratories. Hoechst supplied
Hoe-140 (D-Arg[hydroxyproline3,beta-thienylalanine5,D-Tic7,
octahydroindol-2-yl-carbonylresidue8]-bradykinin).
Data analysis. Data are presented as mean values 6 SD,
unless otherwise indicated. Differences between groups as
function of time were analyzed using a nonparametric
ANOVA for repeated measures (21). After global testing, a
multiple comparison procedure using Bonferroni-Holm adjust-
ment of p was carried out (22). An error probability of p , 0.05
was regarded as significant. Lower levels of p are indicated.
Results
Means of pulmonary arterial pressure (7.0 to 7.4 mm Hg),
coronary flow (30.6 to 32.9 ml/min), contractile performance
(LVPmax, 83 to 90 mm Hg) and heart rate at baseline (179 to
189 beats/min) were nearly identical in all groups observed.
Serial perfusion. In both NZW and WHHL groups, serial
perfusion caused a coronary constriction, which was accompa-
nied by decreases in mechanical performance. These mechan-
ical alterations corresponded to the degree of flow reduction
(9).
During the separate perfusion period, we found in all
groups only ventricular extrasystoles (VES); the incidence of
VES did not differ between the groups (Fig. 1).
Switching from separate to serial perfusion resulted in a
significant increase in the number of VES in both the NZW
and the WHHL groups (Fig. 1). But in WHHL, the incidence
of monomorphic, nonsustained ventricular tachycardia (VT)
was significantly increased in comparison to the NZW group
(1.38 6 1.06 vs. 0.33 6 0.49 VT/40 min, p , 0.05). The VT
could be observed in 6 of 8 hearts in the WHHL group, with a
rate of 250 6 12 beats/min, and in only 4 of 12 hearts in the
NZW group (240 6 10 beats/min). In addition, VT in WHHL
was significantly longer than in NZW (14.36 6 3.07 vs. 7.25 6
1.50 beats/VT, p , 0.05).
The occurrence of both VES and VT throughout the entire
period of serial perfusion was not time-dependent.
Administration of exogenous big ET and ET. In NZW
hearts, coronary infusion of ET-1 and big ET-1, at a concen-
tration of 5 pmol/liter, produced a drop in coronary flow by
14 6 2% (baseline, 32.2 6 2.5; ET, 27.7 6 2.1 ml/min) and 9 6
Figure 1. Incidence of VES during 40 min of separate perfusion and
an additional 40 min of serial perfusion in NZW (n 5 12) and WHHL
(n 5 8) rabbits. During serial perfusion, isolated hearts are perfused
with the effluent of the same animal’s isolated lung. To exclude
flow-dependency of arrhythmias, mechanical flow reduction (i.e.,
volume-controlled perfusion) comparable to the effects seen during
serial perfusion was performed in isolated NZW and WHHL hearts
(M-NZW, New Zealand mechanical flow reduction group; M-WHHL,
Watanabe mechanical flow reduction group, n 5 6 for both groups).
##, p , 0.01 vs. separate perfusion.
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4% (baseline, 31.5 6 2.9; big ET, 28.7 6 1.9 ml/min), respec-
tively. The corresponding flow decreases in WHHL hearts,
measured at 229 6 5% for ET-1 (baseline, 30.9 6 3.0; ET,
21.9 6 1.5 ml/min) and 223 6 4% for big ET-1 (baseline,
31.0 6 2.2; big ET, 23.9 6 1.8 ml/min), were significantly
steeper than those observed in NZW hearts. The effects of
exogenous ET and big ET on ventricular arrhythmias were
comparable to those observed in the NZW and WHHL serial
perfusion groups (Table 1).
Pharmacological interventions. ET antagonists and inhibi-
tion of ECE produced identical results in controls and WHHL
(Fig. 2): Flow reduction, the increase in VES and the oc-
curence of VT were completely eliminated by coronary infu-
sion of phosphoramidon (50 mmol/liter), an ECE inhibitor.
Infusion of the nonselective ET antagonist PD-145065 (10
mmol/liter) as well as the ETA antagonists BQ-123 (2 mmol/
liter) and A-127722 (20 mmol/liter) led to significant but not
complete suppression of VES, whereas VT and the coronary
flow reduction were completely eliminated by these agents.
The ETB antagonists IRL-1038 (4 mmol/liter) and IRL-1025 (5
mmol/liter) had no effect on coronary flow or ventricular
arrhythmias.
In both NZW and WHHL groups, coronary infusion of the
following agents did not influence ventricular arrhythmias
during serial perfusion (data not shown): captopril (5 mmol/
liter), an angiotensin-converting enzyme inhibitor, desArg9-
[Leu]8-bradykinin (5 mmol/liter), a bradykinin-1 receptor an-
tagonist and Hoe-140 (1 mmol/liter), a bradykinin-2 receptor
antagonist. Similarly, pulmonary infusion of the cyclooxygen-
ase inhibitor meclofenamic acid (10 mmol/liter) did not influ-
ence the decrease in coronary flow and the incidence of VES
in either group.
Discussion
Big endothelin-induced arrhythmia: Direct versus isch-
emia-/flow-dependent effects. In this project, we investigated
whether pulmonary big ET is directly arrhythmogenic and, if
so, whether this effect is dependent on coronary conversion to
ET. Until now, conflicting results have appeared concerning
the arrhythmogenic effects of ET and the underlying mecha-
nisms. Previous studies conducted in pigs (6), rats (23) and
dogs (24,25) suggested ischemia-dependent proarrhythmic ef-
fects of intracoronary ET administration. In contrast, the view
that ET may function as a direct mediator of arrhythmogenesis
is supported by findings revealing a higher proarrhythmic
potency of ET compared with mere coronary artery occlusion
(26), a sustentation of ET-induced arrhythmias despite resto-
ration of coronary flow (27), and a dependency on the site of
ET administration of ventricular arrhythmias (27). In addition,
Yorikane et al. (7,8) reported a prolongation of the action
potential duration by ET (200 nmol/liter), followed by the
development of early afterdepolarizations.
Assessment of the direct electrophysiologic effects of ET,
however, is hampered by the fact that the studies cited used
very high doses of ET. Endothelin can be detected in the
plasma of normal humans in concentrations ranging from 0.5
to 5 pmol/liter, and the lowest ET concentrations found to
increase coronary tone, in rabbits, ranged between 1 and 10
pmol/liter (28). Consequently, it is unclear whether endoge-
Figure 2. Incidence of VES in NZW and Watanabe hearts when serial
perfusion (40 min) was conducted in the presence of PD-145065
(nonselective ET antagonist, 10 mmol/liter), A-127722 (ETA antago-
nist, 20 mmol/liter), BQ-123 (ETA antagonist, 2 mmol/liter) and
phosphoramidon (Phrd, ECE inhibitor, 50 mmol/liter) (n 5 6 per
group). #, p , 0.05; ##, p , 0.01 vs. separate perfusion; *, p , 0.05;
**, p , 0.01 vs. serial perfusion without intervention.
Table 1. VES and VT During Infusion of Exogenous Big ET and ET
VES/40 min
Incidence of
VT/40 min Length of VT
NZW (n 5 12) 40.67 6 8.00 0.33 6 0.49 7.25 6 1.50
WHHL (n 5 8) 40.25 6 5.23 1.38 6 1.06* 14.36 6 3.07*
Exogenous Big ET and NZW (n 5 6) 34.83 6 6.91 0.33 6 0.52 5.50 6 0.71
Exogenous ET and NZW (n 5 6) 37.83 6 7.03 0.33 6 0.82 6.50 6 0.71
Exogenous Big ET and WHHL (n 5 6) 42.63 6 7.07 1.33 6 0.82* 15.00 6 2.45*
Exogenous ET and WHHL (n 5 6) 41.86 6 12.56 1.17 6 0.75* 12.29 6 2.06*
Data refer to the 40-min serial perfusion in NZW and WHHL, and to the 40-min infusion of exogenous ET/Big ET.
Length is given as beats/VT. *, p , 0.05, WHHL vs. NZW.
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nous ET/big ET plays a role in the physiological modulation of
myocardial rhythmogenesis.
ECE-dependent proarrhythmic effect of endogenous pul-
monary big ET. Our findings demonstrate that the basal
pulmonary release of big ET, determined at 5.5 to 5.7 pmol/
liter in both groups (9), may induce ventricular arrhythmias
and coronary vasoconstriction. Ventricular arrhythmias were
not accompanied by ECG signs of ischemia, although coronary
flow decreased by 11 6 3% in control rabbits and by 25 6 6%
in the Watanabe group. In addition, mechanical reduction of
coronary flow comparable to the big ET-induced vasoconstric-
tion did not affect the incidence or severity of ventricular
arrhythmias. The arrhythmogenic properties of pulmonary big
ET can, therefore, hardly be explained by flow-dependent
mechanisms. The data obtained in the present study point to a
direct arrhythmogenic property of big ET or ET in our model.
To determine whether this arrhythmogenic effect is due to the
conversion from big ET to ET, or whether big ET itself
possesses arrhythmogenic properties, we intracoronarily in-
fused phosphoramidon, an ECE inhibitor. Phosphoramidon
led to complete elimination of arrhythmias, which confirms
that the proarrhythmic effect of big ET was exclusively caused
by local coronary conversion to ET.
Studies conducted by Brunner (14,29) have revealed proar-
rhythmic effects of endogenous cardiac ET during reperfusion
after low-flow ischemia in isolated rat hearts. We, in contrast,
observed only a mild decrease in coronary flow evoked by
endogenous pulmonary big ET. Therefore, though we cannot
entirely exclude flow redistribution by pulmonary big ET
leading to relative hypoperfusion of certain areas, we did not
study myocardial ischemia in our experiments. This fact may
explain why we were not able to suppress arrhythmias by
coronary application of captopril, which contradicts the find-
ings of Brunner (14), who demonstrated an angiotensin-
endothelin proarrhythmic axis functioning during ischemia/
reperfusion in rat hearts. On the other hand, it is even
uncertain whether or not there are distinct pathways of ET-
mediated arrhythmogenesis during ischemia/reperfusion and
in our experimental setting. This item remains to be examined
in further experimental studies.
Role of endothelin receptor subtypes in arrhythmogenesis.
The question arises as to which receptor mediated these
arrhythmogenic effects. In rats (29,30) and dogs (31), ET-
induced ventricular arrhythmias proved sensitive to ETA
blockade, whereas a contribution of ETB receptors could be
excluded. In the present study, the nonselective ET antagonist
PD-145065 as well as the ETA antagonists BQ-123 and
A-127722 significantly but not entirely hindered ventricular
arrhythmias, although these agents completely prevented cor-
onary constriction. The ETB antagonists IRL-1038 and IRL-
1025 had no effect. Hence, in our model, the proarrhythmic
action of ET is ETB-independent and partly ETA-mediated.
Another still unknown receptor or mechanism seems likely, as
postulated by Kasai et al. (32), for the ET-mediated positive
inotropic effects in rabbit hearts.
Aggravated arrhythmia in heritable hyperlipidemia: Possi-
ble role of endothelial dysfunction. As a key finding, the
Watanabe group disclosed a significantly enhanced severity of
arrhythmias, as indicated by a higher incidence of nonsus-
tained VT. Despite the 2.5-fold stronger coronary vasocon-
strictor effect of pulmonary big ET in this group, there was no
evidence of ischemia-induced ventricular arrhythmias—an
identical mechanical reduction of coronary flow produced no
increase in arrhythmias.
We have recently shown that the Watanabe rabbits em-
ployed in our investigation suffered from coronary endothelial
dysfunction (9). Impairment of endothelial function exists even
before histological findings of atherosclerosis become apparent
(33,34). The endothelial dysfunction affects both the nitric
oxide (35) and the prostacyclin (36) pathway. Studies in dogs
(37) and rats (38) have implicated nitric oxide as an endoge-
nous mediator of preconditioning against severe ventricular
arrhythmias. Similarly, it has been suggested that prostacyclin
represents an antiarrhythmic substance (39,40). Hence, dete-
rioration of ET function probably leads to higher susceptibility
to arrhythmia, which could account for the difference observed
between controls and WHHL.
Study limitations. With respect to the release of big ET
observed, the question might arise whether the perfusate
characteristics—that is, the absence of blood cells and plasma
proteins—that is, the absence of blood cells and plasma
proteins—may have influenced this key finding. Brunner and
co-workers (41), however, have demonstrated that binding of
ET to albumin does not affect the vasoactivity of ET. Further-
more, circulating blood has been excluded as a major site of big
ET conversion (42) and clearance (43). As a result, the release
of big ET described in this study is in all probability largely
independent of the artificial conditions applied.
Concerning the enhanced severity of arrhythmia found in
WHHL, this study does not provide direct proof that endothe-
lial dysfunction represents the underlying mechanism. Al-
though this explanation seems reasonable in the light of
numerous studies revealing the antiarrhythmic effects of nitric
oxide and prostacyclin, we cannot exclude additional arrhyth-
mogenic properties inherent in WHHL isolated hearts.
Potential clinical implications. With respect to the poten-
tial clinical implications of our findings, attention should be
directed to the severe ventricular arrhythmias that are charac-
teristic of advanced chronic heart failure. Plasma concentra-
tions of big ET (44), as well as pulmonary synthesis of ET (45),
are known to increase with the severity of the disease. This
increment in ET production is accompanied by an elevated
expression of ET receptors (46). Furthermore, an important
percentage of chronic heart failure develops on the basis of
ischemic heart disease, in which endothelial dysfunction is
common. In light of these clinical facts and our experimental
findings showing enhanced severity of big ET-induced arrhyth-
mias in heritable hyperlipidemia, we hypothesize that ET, in
general, and pulmonary big ET, in particular, may act as an
important mediator of arrhythmogenesis in chronic heart
failure.
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